康惠制药(603139.SH)发布上半年业绩，归母净亏损4020.36万元，扩大362.01%

Core Viewpoint - Kanghui Pharmaceutical (603139.SH) reported a decline in revenue and an increase in net losses for the first half of 2025, indicating financial challenges for the company [1] Financial Performance - The company's operating revenue for the first half of 2025 was 248 million yuan, a year-on-year decrease of 6.83% [1] - The net loss attributable to shareholders of the listed company was 40.2036 million yuan, which represents a year-on-year increase of 362.01% [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 42.8271 million yuan, reflecting a year-on-year increase of 167.89% [1] - The basic loss per share was 0.4 yuan [1]